Use of a quality-by-design approach to justify removal of the HPLC weight % assay from routine API stability testing protocols.
Due to the high method variability (typically > or = 0.5%, based on a literature survey and internal Merck experience) encountered in the HPLC weight percent (%) assays of various active pharmaceutical ingredients (APIs), it is proposed that the routine use of the test in stability studies should be discouraged on the basis that it is frequently not sufficiently precise to yield results that are stability-indicating. The high method variability of HPLC weight % methods is not consistent with the current ICH practice of reporting impurities/degradation products down to the 0.05% level, and it can lead to erroneous out-of-specification (OOS) results that are due to experimental error and are not attributable to API degradation. For the vast majority of cases, the HPLC impurity profile provides much better (earlier and more sensitive) detection of low-level degradation products. Based on these observations, a Quality-by-Design (QbD) approach is proposed to phase out the HPLC weight % assay from routine API stability testing protocols.
Skrdla
Peter J
PJ
Merck & Co., Inc., P.O. Box 2000, 126 East Lincoln Avenue, RY818-B205, Rahway, NJ 07065, USA. peter_skrdla@merck.com
Wang
Tao
T
Antonucci
Vincent
V
Dowling
Thomas
T
Ge
Zhihong
Z
Ellison
Dean
D
Curran
John
J
Mohan
Ganapathy
G
Wyvratt
Jean
J
D002626:Chemistry, Pharmaceutical / Q000379:methods* / Q000592:standards*; D002851:Chromatography, High Pressure Liquid / Q000379:methods* / Q000592:standards*; D004339:Drug Compounding; D004340:Drug Contamination; D004345:Drug Industry; D004355:Drug Stability; D004364:Pharmaceutical Preparations / Q000032:analysis; D011786:Quality Control; D015203:Reproducibility of Results; D013678:Technology, Pharmaceutical / Q000379:methods / Q000592:standards
D004364:Pharmaceutical Preparations